Weekly Financing | 3.12-3.18 National Medical and Health Industry Financing Inventory

At the beginning of this week, the total domestic financing increased by about 241% month-on-month, and the biomedicine field continued to rise.

As of March 25, there have been more than 25 financing projects in the medical and health industry across the country, 14 of which have exceeded 100 million yuan, covering biomedicine, medical equipment, genetic testing, biotechnology, medical AI and other tracks.

Starting from the trend, Flint creates the "National Medical and Health Investment and Financing Weekly".

In March (03.

The subdivisions with a large number of financing projects are: pharmaceuticals (11 cases, accounting for 44%), medical devices (4 cases, 16%), biotechnology (4 cases, 16%), industrial services (3 cases, 12 cases %).

The financing projects were concentrated in Shanghai (7 cases), Zhejiang Province (5 cases), Beijing, Guangdong Province and Jiangsu Province each accounted for (3 cases), and the total number of financing projects accounted for about 84%.

Figure 1: The financing situation in March 2021

Source: Flint Creation Database

01 Overview of financing this week

1.

This week (03.

The largest amount of financing disclosed this week:

On March 23, 2021 Eastern Time, Brii Biosciences, a multinational company dedicated to the development of innovative therapies, announced that it has completed a US$155 million Series C financing for the treatment of diseases with major medical needs and a huge public health burden .

This round of financing was led by the Invesco Developing Markets Fund, with the participation of other new and existing investors.

The second largest financing project disclosed this week:

Recently, Biopharmaceuticals, a clinical-stage biopharmaceutical company focusing on the development of innovative double-antibody drugs, announced the completion of a US$120 million Series C financing.

This round of financing was jointly led by CMB International CMBI and Mirae Asset Financial Group of South Korea’s Mirae Asset Financial Group, with well-known investments such as Hony Capital, Osprey Asset Management, Yanchuang Capital, Octagon Capital, cultural entrepreneur and investor Zheng Zhigang, and Shangwan Capital.

China Renaissance Capital acted as the exclusive financial advisor for this transaction.

The third-largest financing project disclosed this week:

Zhejiang Jianxin Force Pharmaceutical Co.

China Renaissance Capital acted as the exclusive financial advisor for this transaction.

Table 1: This week (03.

Source: Flint Creation Database

2.
Distribution of financing stages

This week, the number of domestic medical and health industry financing projects concentrated in the A and B rounds (including Pre-A, A, A+, A++, and B), a total of 11 cases, accounting for about 44% of the total number of projects; strategic financing and There are 3 rounds of C financing, each accounting for about 12% of the total number of projects.
The total amount of C round financing in each round of financing amounted to 2.
277 billion yuan, accounting for about 36.
75% of the total amount this week.

Figure 2: The number and amount of each round of financing this week (03.
19-03.
25)

Source: Flint Creation Database

02 Overview of Financing in Subdivisions

In the subdivisions, the number of financing projects in the pharmaceutical field was 11, accounting for 44% of the total financing projects; the number of financing projects in the medical device and biotechnology fields was 4, each accounting for 16% of the total number of projects; the number of financing projects in the industrial service field 3 cases, accounting for 12% of the total financing projects; this week, the financing amount in the pharmaceutical field was 4.
941 billion yuan, accounting for 76.
38% of the total financing amount.

Figure 3: This week (03.
19-03.
25) the number and distribution of financing in sub-sectors

Source: Flint Creation Database

drug

The largest financing amount in the pharmaceutical sector this week came from Tengshengbo Pharmaceutical Technology (Shanghai) Co.
, Ltd.
The multinational company Brii Biosciences is committed to developing innovative therapies for the treatment of diseases with major medical needs and a huge public health burden.
It recently announced the completion of a $155 million Series C financing.

This round of financing was led by the Invesco Developing Markets Fund, with the participation of other new and existing investors.
Among them, new investors also include Singapore Government Investment Corporation (GIC) and a world-leading investment institution.
In addition, Lake Bleu Capital and a leading Asian investment institution, as well as three existing investors are also participating This round of financing.

The funds raised will be used to promote Tengshengbo's rich infectious disease project and the company's central nervous system disease project.
In the future, it will continue to provide China with innovative drugs as a way to improve public health.

Dr.
Hong Zhi, CEO of Tengshengbo Pharmaceutical, said, “Since its establishment in 2018, Tengshengbo Pharmaceutical has achieved significant achievements in the mission of accelerating the development and launch of breakthrough drugs through strategic cooperation and unique insights into the discovery of differentiated drugs.
Progress.
We are very pleased and honored to receive the support of investors and work with us to discover, develop and implement innovative therapies for patients in China and the world, and to solve the world’s major public health problems and disease burdens.
This is our common duty of.
"

Table 2: This week (03.
19-03.
25) TOP10 financing projects in the pharmaceutical field

Source: Flint Creation Database

03 Overview of the geographical distribution of financing

This week's financing projects are mainly distributed in Shanghai, Zhejiang, Beijing, Guangdong and Jiangsu.
The total number of financing projects is 21, accounting for about 84%.
Among them, there are 7 financing projects in Shanghai, accounting for 28% of the total financing projects this week; 5 financing projects in Zhejiang, accounting for 20% of the total financing projects this week; Beijing, Guangdong and Jiangsu financing projects each, accounting for 3 financing projects this week 12% of the total number of financing projects; in addition, the amount of financing in Shanghai this week was 3.
345 billion yuan, accounting for 51.
70% of the total financing.

Figure 4: This week (03.
19-03.
25) the number and amount of regional financing

Source: Flint Creation Database

Table 3: (03.
19-03.
25) Financing situation of the top 5 medical and health industries in Shanghai

Source: According to public information

04 List of financing events this week

Active investment institutions in the healthcare industry this week: Sequoia Capital China (3 cases), CMB International Capital (3 cases), IDG Capital (2 cases), Jifeng Capital (2 cases), Eli Lilly Asia Fund (2 cases), Xia Erba Investment (2 cases), Yanchuang Capital (2 cases).

Table 4: List of financing events in the healthcare industry this week (03.
19-03.
25)

Source: Flint Creation Database

Conclusion

This week’s financing cases and the amount of financing have increased substantially compared to last week.
The possible areas that have attracted new media and the attention of the whole people are low-price competition in the market of medical elements that are volume-for-price.
The possible directions include medicines, consumables, devices or vaccines.

The investment in the biomedicine sector is still in a steady ascending stage this year.
First-tier cities such as Shanghai, Zhejiang, and Beijing are still key areas for attracting investment.
Guangdong and Jiangsu, which have a number of leading companies, are also key areas for capital attention.